Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CALR allele burden quantification

PreclinicalBiologic

UUniversity Hospital, Angers

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myeloproliferative SyndromeRecruiting

Myeloproliferative SyndromePreclinical

Recruiting

Timeline

Expected Milestones

Q2 2030

Myeloproliferative Syndrome

NCT04942080

Clinical

Trials by Indication[1]

Myeloproliferative Syndrome1 trial

Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)

Recruiting·UUniversity Hospital, Angers·N/A·NCT04942080·260 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CALR allele burden quantification. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CALR allele burden quantification compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CALR allele burden quantification. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Angers company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Angers

Related News